Vaccine candidates Pfizer, AstraZeneca lead DOST ranking on efficacy, safety

Ina Reformina, ABS-CBN News

Posted at Jan 15 2021 07:50 PM | Updated as of Jan 15 2021 08:31 PM

MANILA — Pfizer and AstraZeneca’s COVID-19 vaccine led the Department of Science and Technology’s (DOST) vaccine ranking released on Friday, based on safety, potential efficacy, stability and the company’s track record.

Novavax and Sinovac ranked third and fourth, respectively, according to DOST’s vaccine panel. 

Dr. Jaime Montoya, executive director of the Philippine Council for Health Research and Development, said the ranking was based on a number of criteria, which include:

 

Pfizer’s vaccine is the only one included in the World Health Organization’s emergency list. Among other vaccine frontrunners, it also has EUAs in the most number of countries.

An EUA allows Pfizer’s vaccine to be imported, distributed and administered in the Philippines through a national immunization program.

Food and Drug Administration (FDA) Director General Eric Domingo earlier said the vaccine, based on interim data of Phase 3 trials, has an efficacy rate of 95 percent. The efficacy rate for all racial groups was at 92 percent. 

The country, meanwhile, has so far secured 17 million doses of the AstraZeneca vaccine, with the help of the private firms and local governments.